// App-Quantinova.ai

DMT48 : Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from Prevent

Researchers

Presenter

  • Michael Levy

Principal Investigators

  • Achim Berthele

  • Ho Jin Kim

  • Kazuo Fujihara

  • Ichiro Nakashima

  • Celia Oreja-Guevara

  • Jacqueline Palace

  • Sean J Pittock

  • Murat Terzi

  • Natalia Totolyan

  • Shanthi Viswanathan

  • Kai-Chen Wang

  • Amy Pace

  • Marcus Yountz

  • Diane Lawson

  • Eva Laudon-Meyer

  • Dean Wingerchuk

Medical Centers

  • Hospital Universitario Clinico San Carlos, Madrid, Spain

  • Alexion Pharmaceuticals, Boston, MA

  • National Medical University, St Petersburg, Russian Federation

  • Massachusetts General Hospital and Harvard Medical School, Boston, MA, Johns Hopkins University, Baltimore, MD

  • Medicine, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia

  • Research Institute and Hospital of National Cancer Center, Goyang, KOREA, REPUBLIC OF

  • Mayo Clinic, Scottsdale, AZ

  • John Radcliffe Hospital, Oxford, United Kingdom.

  • Mayo Clinic, Rochester, MN

  • Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany

  • Ondokuzmayis University, Samsun, Turkey

  • Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, Japan, Tohoku University, Sendai, Japan, Fukushima Medical University, Fukushima City, Japan

  • Alexion Pharmaceuticals GmbH,Zürich,Switzerland

  • Tohoku Medical and Pharmaceutical University, Sendai, Japan, Tohoku University, Sendai, Japan

  • School of Medicine, National Yang Ming University, Taipei, Taiwan, Cheng-Hsin General Hospital, Taipei, Taiwan

Locations

  • Spain

  • United States

  • Germany

  • Turkey

  • Japan

  • Malaysia

  • Switzerland

  • Taiwan

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Central Nervous System (CNS)

Disease

  • Neuromyelitis optica

Biomarkers

  • N/A

Drug/Treatment

  • Intratect

  • Mitoxantrone

  • Eculizumab

  • Rituximab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • NCT01892345

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved